Evidence map›Paper›PMID 36233063›Full record

ArticleInternational journal of molecular sciences2022

RYBP Sensitizes Cancer Cells to PARP Inhibitors by Regulating ATM Activity.

Deanna V Maybee, Alexandra Maria Psaras, Tracy A Brooks, Mohammad A M Ali

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Deanna V MaybeeDepartment of Pharmaceutical Sciences, SUNY Binghamton University School of Pharmacy and Pharmaceutical Sciences, Binghamton, NY 13790, USA.
Alexandra Maria PsarasDepartment of Pharmaceutical Sciences, SUNY Binghamton University School of Pharmacy and Pharmaceutical Sciences, Binghamton, NY 13790, USA.ORCID 0000-0002-4978-6003
Tracy A BrooksDepartment of Pharmaceutical Sciences, SUNY Binghamton University School of Pharmacy and Pharmaceutical Sciences, Binghamton, NY 13790, USA.
Mohammad A M AliDepartment of Pharmaceutical Sciences, SUNY Binghamton University School of Pharmacy and Pharmaceutical Sciences, Binghamton, NY 13790, USA.ORCID 0000-0002-6404-4198
Binghamton University · US

Funding

State University of New York 910252-50
6 · The paper itself

Abstract

Ring1 and YY1 Binding Protein (RYBP) is a member of the non-canonical polycomb repressive complex 1 (PRC1), and like other PRC1 members, it is best described as a transcriptional regulator. Previously, we showed that RYBP, along with other PRC1 members, is also involved in the DNA damage response. RYBP inhibits recruitment of breast cancer gene 1(BRCA1) complex to DNA damage sites through its binding to K63-linked ubiquitin chains. In addition, ataxia telangiectasia mutated (ATM) kinase serves as an important sensor kinase in early stages of DNA damage response. Here, we report that overexpression of RYBP results in inhibition in both ATM activity and recruitment to DNA damage sites. Cells expressing RYBP show less phosphorylation of the ATM substrate, Chk2, after DNA damage. Due to its ability to inhibit ATM activity, we find that RYBP sensitizes cancer cells to poly-ADP-ribose polymerase (PARP) inhibitors. Although we find a synergistic effect between PARP inhibitor and ATM inhibitor in cancer cells, this synergy is lost in cells expressing RYBP. We also show that overexpression of RYBP hinders cancer cell migration through, at least in part, ATM inhibition. We provide new mechanism(s) by which RYBP expression may sensitize cancer cells to DNA damaging agents and inhibits cancer metastasis.

Indexed as

Ataxia Telangiectasia Mutated ProteinsNeoplasmsPoly(ADP-ribose) Polymerase InhibitorsRepressor ProteinsAdenosine Diphosphate RiboseCarrier ProteinsCell Cycle ProteinsDNA DamageHumansPolycomb Repressive Complex 1UbiquitinsAdenosine Diphosphate RiboseAtaxia Telangiectasia Mutated ProteinsATM protein, humanCarrier ProteinsCell Cycle ProteinsPoly(ADP-ribose) Polymerase InhibitorsPolycomb Repressive Complex 1Repressor ProteinsRYBP protein, humanUbiquitinsataxia telangiectasia mutated (ATM)checkpoint kinase 2 (Chk2)DNA damage response (DDR)poly-ADP-ribose polymerase (PARP)Ring1 and YY1 Binding Protein (RYBP)

Identifiers

PMID36233063
PMCPMC9570458
OpenAlexW4303699462

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.